Abstract
Inhalational Therapy has a wide range of products which are frequently being used for the treatment of Obstructive Lung Disease which generally includes COPD & Asthma. The prevalence of death due to the disease is being found as 3 million each year which is being increasing and at present it is third leading cause of death worldwide. This pharmacovigilance study is a prospective cohort study carried out at SAIMS hospital, Indore. The study is designed to monitor factual clinical trends in the treatment of OLD and to evaluate the correlation between different therapy of inhaled bronchodilator and their outcome. A total of 100 out patients were enrolled in the study after an informed consent, out of which 58 were males and 42 females. Causality assessment was done using the Naranjo’s Scale & severity was analysed using Hatwing & Siegel Scale severity scale. 32 % of ADR were attributed in the study cohort of 100 patients. Common ADRs observed with drug treatment were diarrhoea, altered bowel habits, gastritis, tachycardia, headache & muscle cramps. The prevalence of ADR was more in GIT, CVS and other organs. CNS ADRs were less reported. The present study resulted in 60 % of ADR which were observed as mild & 40 % reported to be moderate. No severe ADRs were reported. Out of all ADRs, 37.14 % belongs to Doubtful ≤ 0 category, 25.71 % belongs to possible 1-4 category, 28.57 % belongs to probable 5-8 category and 8.57 % belongs to highly probable ≥ 9 categories. Thus, this study compliance the use of inhaled bronchodilator with no severe ADR at each category (children, adult & elderly) and urges for the use of inhalational therapy.
Keywords: Pharmacovigilance, ADR.
References
- Bronchodilators [online]. [Cited on 2020 Feb 29]; Available from: https://www.medicinenet.com/bronchodilators_for_asthma/article.htm#what_are_bronchodilators_and_how_do_they_work
- Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory Society, 2017.
- Inhaled Bronchodilators [Online]. [Cited on 2020 Feb 29]; Available from:https://www.webmd.com/asthma/guide/asthma_inhalers_bronchodilators#1
- ADR Reporting Form. 2013[Cited on 2013 mar 22] ; Available from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdfdocuments/Consumer_Section_PDFs/ADRRF_2.pdf
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239-45
- Hartwig SC1, Siegel J, Schneider PJ.,Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992 Sep;49(9):2229-32.
- Side effects of bronchodilator r[online]. 2013 [cited on 12 mar 2013]; Available from: https://www.nhs.uk/conditions/bronchodilators/side-effects/
- Masoli M, Fabian D, Holt S, BeasleyR; Global Initiative for Asthma (GINA) Program The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004 May; 59(5):469-78.
- Rabe KF, Hurd S, Anzueto A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. 2007; Available from: http://en.wikipedia.org/COPD
- Sangeetha Purushothaman, Gangadhar Reneega, K Kumari Anitha, Nair Sanjeev. Adverse Drug Monitoring in Chronic Obstructive Pulmonary Disease Patients in a Tertiary Care Cenre. JMSCR. April 2017;05(04):19884-89
- Tyagi N, Gulati, Vijayan VK, Ray A. A study to monitor adverse drug reactions in patients of chronic obstructive pulmonary disease. I J Chest disease & Allied Sci. 2008; vol. 50: 199-202
- Lokesh kumar. Pharmacovigilance/ reporting adverse drug reactions: an approach to enhance health surveillance and extending market share by minimizing the chances of drug withdrawals. Int J Pharm Pharm Sci. 7(9); 1-7
- V Kalaiselvan, Prasad Thota1 and Abishank Singh. Current Status of Adverse Drug Reactions Monitoring Centres under Pharmacovigilance Programme of India, Indian Journal of Pharmacy Practice. Jul–Sep, 2014; 7(3).
Corresponding Author
Shweta Bhandari
Assistant Professor, Dept. of Pharmacology, Mahatma Gandhi College of Pharmaceutical Sciences, Jaipur
DOI: https://dx.doi.org/10.18535/jmscr/v8i3.10
